Zhu et al., 2020 - Google Patents
Effect of atorvastatin on pulmonary hypertension rats through regulating notch signaling pathway.Zhu et al., 2020
View PDF- Document ID
- 11595227289300872557
- Author
- Zhu Y
- Liu H
- Zhang X
- Tang M
- Liu J
- Cao G
- Publication year
- Publication venue
- European Review for Medical & Pharmacological Sciences
External Links
Snippet
OBJECTIVE: To study the effect of atorvastatin on pulmonary hypertension (PAH) rats through regulating the Notch signaling pathway. MATERIALS AND METHODS: The rat model of PAH was established via hypoxic feeding and the Control group (n= 10), PAH …
- 241000700159 Rattus 0 title abstract description 33
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation | |
| De Visser et al. | Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury | |
| EP3307286B1 (en) | Allogeneic mammalian amniotic exosomes for treating a fibrotic disease | |
| Battu et al. | Amino acid starvation sensing dampens IL-1β production by activating riboclustering and autophagy | |
| US20230053540A1 (en) | Treatment of liver injury | |
| Zhang et al. | Inhibition of Rac1 activity alleviates PM2. 5-induced pulmonary inflammation via the AKT signaling pathway | |
| De Luca et al. | Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review | |
| Ghali et al. | IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture | |
| Zhou et al. | Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction | |
| Dai et al. | microRNA-145 inhibition upregulates SIRT1 and attenuates autophagy in a mouse model of lung ischemia/reperfusion injury via NF-κB-dependent Beclin 1 | |
| WO2023020212A1 (en) | Use of drd2 inhibitor in preparation of drug for treating diseases associated with liver fibrosis | |
| Ambler et al. | Vascular damage in systemic lupus erythematosus | |
| Chai et al. | Downregulation of PDCD4 through STAT3/ATF6/autophagy mediates MIF-induced PASMCs proliferation/migration and vascular remodeling | |
| Zhu et al. | Effect of atorvastatin on pulmonary hypertension rats through regulating notch signaling pathway. | |
| TW202106313A (en) | Pharmaceutical composition for treating sepsis or systemic inflammatory response syndrome comprising isolated mitochondria as effective ingredient | |
| Galichon et al. | Stress response gene Nupr1 alleviates cyclosporin A nephrotoxicity in vivo | |
| Liu et al. | Circulating fibrocytes are involved in inflammation and leukocyte trafficking in neonates with necrotizing enterocolitis | |
| Berair et al. | Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma | |
| Lingappan et al. | Molecular insights using spatial transcriptomics of the distal lung in congenital diaphragmatic hernia | |
| Zhao et al. | Targeting progranulin alleviated silica particles-induced pulmonary inflammation and fibrosis via decreasing Il-6 and Tgf-β1/Smad | |
| JP2023503804A (en) | IL-34 antisense agents and methods of using same | |
| US20200230115A1 (en) | Methods of treating influenza-associated viral pneumonia | |
| US20210252003A1 (en) | Protein Kinase RNA-Like Endoplasmic Reticulum Kinase (PERK) Inhibitors for Prevention and/or Treatment of Lung Injury and/or Inflammation | |
| Chen et al. | ANP attenuates intestinal inflammation by regulating STING pathway | |
| WO2022047128A2 (en) | Method for treating complement mediated disorders caused by betacoronaviruses |